COMPUGEN LTD: directors' dealings · United States · SEC (Form 4)

About COMPUGEN LTD

Compugen Ltd. (Nasdaq: CGEN) is a clinical-stage biotechnology company listed on the NASDAQ market in the United States, focused on oncology immunotherapy and computational discovery of novel therapeutic targets using AI/ML. Founded in 1993 and historically established in Israel, the company is headquartered in Holon, Israel, and maintains a U.S. subsidiary, Compugen USA, Inc., to support development activities and market-facing operations. For investors, the key point is that Compugen is not a traditional commercial pharma company; its business model is built around early scientific discovery, clinical development, and value realization through collaborations, licensing, milestone payments, and royalties. Compugen’s competitive position is anchored by Unigen™, its proprietary computational discovery platform. The platform combines deep biology expertise, predictive algorithms, and multi-omics data to identify novel immune-oncology mechanisms that may not be easily found through conventional wet-lab approaches alone. This differentiated model is designed to generate potentially first-in-class or best-in-class programs, which is an important advantage in a highly competitive oncology landscape where scientific novelty and translational validation drive long-term value. Its key clinical assets include COM701, a potentially first-in-class anti-PVRIG antibody, and GS-0321 (formerly COM503), a high-affinity anti-IL-18BP antibody licensed to Gilead. Compugen also retains internal development exposure around TIGIT biology, while AstraZeneca is advancing rilvegostomig, a PD-1/TIGIT bispecific derived from Compugen’s collaboration. Geographically, the company operates from Israel but runs and supports clinical development across multiple jurisdictions, including the United States, Israel, and France. This cross-border footprint matters because it gives Compugen access to major clinical networks, regulatory pathways, and research talent pools in oncology. At the same time, investors should recognize the usual biotech risks: high R&D spend, dependence on clinical readouts, partnership execution, and the need for disciplined capital management. Recent company developments are notable. In March 2026, Compugen said it had strengthened its financial position through a non-dilutive transaction with AstraZeneca that monetized a portion of future rilvegostomig royalties and extended expected cash runway into 2029. The company also reported progress on clinical execution, including initiation of trials for COM701 in the MAIA-ovarian program and for Gilead-partnered GS-0321, plus an expanded global clinical footprint. Management changes also matter: Eran Ophir was appointed President and CEO, reflecting a leadership reset aimed at sharper execution. Overall, Compugen offers a compelling innovation-led oncology story, but one that remains highly dependent on clinical success and partner-driven value creation.